First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).

被引：0
|
作者：
Di Giacomo, Anna Maria
Santangelo, Federica
Amato, Giovanni
Simonetti, Elena
Graham, Jill
Lahn, Michael M. F.
Di Conza, Giusy
Hammett, Tracey
Zorrilla, Rebeca
Durini, Marco
Tan, Ziyang
Tadepally, Lakshmikanth
Brodin, Petter
Occhipinti, Mariaelena
Simonelli, Matteo
Carlo-Stella, Carmelo
Santoro, Armando
Spiliopoulou, Pavlina
Evans, T. R. Jeffry
Maio, Michele
机构：
[1] Univ Hosp Siena, Ctr Immuno Oncol, Siena, Italy
[2] Azienda Osped Univ Senese, UOC Immunoterapia Oncolog, Siena, Italy
[3] Univ Siena, Siena, Italy
[4] Beatson Canc Ctr, Glasgow, Lanark, Scotland
[5] iOnctura SA, Geneva, Switzerland
[6] Covance Clin & Peri Approval Serv LTD, Milan, Italy
[7] Karolinska Inst, Stockholm, Sweden
[8] Karolinska Inst, Dept Womens & Childrens Hlth, Sci Life Lab, Solna, Sweden
[9] Radiomics, Liege, Belgium
[10] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[11] Humanitas Univ, Milan, Italy
[12] IRCCS Humanitas Res Hosp, Milan, Italy
[13] IRCCS Humanitas Res Hosp, Rozzano, Italy
[14] Princess Margaret Canc Ctr Canada, Toronto, ON, Canada
[15] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3110
引用
收藏
页数：1
相关论文
共 50 条
  • [21] GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase la dose escalation study.
    Juric, Dejan
    Krop, Ian
    Ramanathan, Ramesh K.
    Xiao, Jim
    Sanabria, Sandra
    Wilson, Timothy R.
    Choi, YounJeong
    Parmar, Hema
    Hsu, Jerry
    Baselga, Jose
    Von Hoff, Daniel D.
    CANCER RESEARCH, 2013, 73 (08)
  • [22] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors
    Baselga, J.
    De Jonge, M. J.
    Rodon, J.
    Burris, H. A., III
    Birle, D. C.
    De Buck, S. S.
    Demanse, D.
    Ru, Q. C.
    Goldbrunner, M.
    Bendell, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
    Tibes, Raoul
    Fine, Gil
    Choy, Gavin
    Redkar, Sanjeev
    Taverna, Pietro
    Oganesian, Aram
    Sahai, Amarpal
    Azab, Mohammad
    Tolcher, Anthony W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 463 - 471
  • [25] A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
    Raoul Tibes
    Gil Fine
    Gavin Choy
    Sanjeev Redkar
    Pietro Taverna
    Aram Oganesian
    Amarpal Sahai
    Mohammad Azab
    Anthony W. Tolcher
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 463 - 471
  • [26] A first-in-human Phase I study of ZSTK474, an oral pan-PI3K inhibitor, in patients with advanced solid malignancies
    Lockhart, Albert C.
    Olszanski, Anthony J.
    Allgren, Robin L.
    Yaguchi, Shinichi
    Cohen, Steven J.
    Hilton, John F.
    Wang-Gillam, Andrea
    Shapiro, Geoffrey I.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [27] Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
    Bendell, Johanna C.
    Rodon, Jordi
    Burris, Howard A.
    de Jonge, Maja
    Verweij, Jaap
    Birle, Diana
    Demanse, David
    De Buck, Stefan S.
    Ru, Qinhua C.
    Peters, Malte
    Goldbrunner, Michael
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 282 - 290
  • [28] First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.
    Sahin, Ugur
    Jaeger, Dirk
    Marme, Frederik
    Mavratzas, Athanasios
    Krauss, Juergen
    De Greve, Jacques
    Vergote, Ignace
    Tureci, Oezlem
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors (vol 7, pg 704, 2017)
    Baselga, Jose
    CANCER DISCOVERY, 2018, 8 (11) : 1491 - 1491
  • [30] A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.
    Wagner, A. J.
    Bendell, J. C.
    Dolly, S.
    Morgan, J. A.
    Ware, J. A.
    Fredrickson, J.
    Mazina, K. E.
    Lauchle, J. O.
    Burris, H. A.
    De Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345